{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T04:11:22Z","timestamp":1750219882779,"version":"3.41.0"},"reference-count":67,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","pet.theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["PET Clinics"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.cpet.2025.01.003","type":"journal-article","created":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T08:59:31Z","timestamp":1738832371000},"page":"175-183","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Current Approaches to Radiation Oncology Target Volume Delineation Using PET\/Computed Tomography"],"prefix":"10.1016","volume":"20","author":[{"given":"Matthew T.","family":"McMillan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven J.","family":"Feigenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"II","given":"Charles B.","family":"Simone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.cpet.2025.01.003_bib1","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.semradonc.2018.02.001","article-title":"Use of PET and other functional imaging to guide target delineation in radiation oncology","volume":"28","author":"Verma","year":"2018","journal-title":"Semin Radiat Oncol"},{"issue":"3","key":"10.1016\/j.cpet.2025.01.003_bib2","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.tibs.2015.12.001","article-title":"The Warburg Effect: how does it benefit cancer cells?","volume":"41","author":"Liberti","year":"2016","journal-title":"Trends Biochem Sci"},{"issue":"1","key":"10.1016\/j.cpet.2025.01.003_bib3","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.cpet.2019.08.002","article-title":"The role of positron emission tomography imaging in radiotherapy target delineation","volume":"15","author":"Menon","year":"2020","journal-title":"Pet Clin"},{"key":"10.1016\/j.cpet.2025.01.003_bib4","unstructured":"Food and Drug Administration US. Review of F-18 fluoro-2-deoxyglucose (F-18 FDG) positron emission tomography in the evaluation of malignancy. 1999. Available at: https:\/\/www.fda.gov\/drugs\/pharmaceutical-quality-resources\/review-f-18-fluoro-2-deoxyglucose-f-18-fdg-positron-emission-tomography-evaluation-malignancy-august (Accessed 31 January 2025)."},{"issue":"10","key":"10.1016\/j.cpet.2025.01.003_bib5","first-page":"4219","article-title":"Biological correlation of 18F-FDG uptake on PET in pulmonary neuroendocrine tumors","volume":"33","author":"Kaira","year":"2013","journal-title":"Anticancer Res"},{"issue":"1","key":"10.1016\/j.cpet.2025.01.003_bib6","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.cpet.2019.08.003","article-title":"Evolving role of novel quantitative PET techniques to detect radiation-induced complications","volume":"15","author":"Dreyfuss","year":"2020","journal-title":"Pet Clin"},{"issue":"5","key":"10.1016\/j.cpet.2025.01.003_bib7","first-page":"415","article-title":"Implementation of FDG-PET\/CT imaging methodology for quantification of inflammatory response in patients with locally advanced non-small cell lung cancer: results from the ACRIN 6668\/RTOG 0235 trial","volume":"11","author":"Jahangiri","year":"2021","journal-title":"Am J Nucl Med Mol Imaging"},{"issue":"4","key":"10.1016\/j.cpet.2025.01.003_bib8","doi-asserted-by":"crossref","first-page":"520","DOI":"10.2967\/jnumed.123.266965","article-title":"An 18F-FDG PET\/CT and mean lung dose model to predict early radiation pneumonitis in stage III non-small cell lung cancer patients treated with chemoradiation and immunotherapy","volume":"65","author":"Thor","year":"2024","journal-title":"J\u00a0Nucl Med"},{"issue":"3","key":"10.1016\/j.cpet.2025.01.003_bib9","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.cpet.2016.03.001","article-title":"PET-based thoracic radiation oncology","volume":"11","author":"Simone","year":"2016","journal-title":"Pet Clin"},{"issue":"4","key":"10.1016\/j.cpet.2025.01.003_bib10","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1056\/NEJM200007273430404","article-title":"Preoperative staging of non-small-cell lung cancer with positron-emission tomography","volume":"343","author":"Pieterman","year":"2000","journal-title":"N\u00a0Engl J Med"},{"issue":"25","key":"10.1016\/j.cpet.2025.01.003_bib11","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1056\/NEJMoa022136","article-title":"Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography","volume":"348","author":"Lardinois","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.cpet.2025.01.003_bib12","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1097\/JTO.0b013e31828e8996","article-title":"Impact of PET staging in limited-stage small-cell lung cancer","volume":"8","author":"Xanthopoulos","year":"2013","journal-title":"J\u00a0Thorac Oncol"},{"issue":"2","key":"10.1016\/j.cpet.2025.01.003_bib13","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1093\/annonc\/mdl374","article-title":"A\u00a0prospective study of PET\/CT in initial staging of small-cell lung cancer: comparison with CT, bone scintigraphy and bone marrow analysis","volume":"18","author":"Fischer","year":"2007","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.cpet.2025.01.003_bib14","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.cllc.2013.08.004","article-title":"Stage migration in planning PET\/CT scans in patients due to receive radiotherapy for non-small-cell lung cancer","volume":"15","author":"Geiger","year":"2014","journal-title":"Clin Lung Cancer"},{"issue":"35","key":"10.1016\/j.cpet.2025.01.003_bib15","doi-asserted-by":"crossref","first-page":"5557","DOI":"10.1200\/JCO.2007.13.2191","article-title":"Involved-field radiation therapy for inoperable non small-cell lung cancer","volume":"25","author":"Rosenzweig","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.cpet.2025.01.003_bib16","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.ijrobp.2004.12.019","article-title":"Selective mediastinal node irradiation based on FDG-PET scan data in patients with non-small-cell lung cancer: a prospective clinical study","volume":"62","author":"De Ruysscher","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"10.1016\/j.cpet.2025.01.003_bib17","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S1470-2045(20)30013-9","article-title":"Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a multicentre, open-label, randomised, controlled trial","volume":"21","author":"Nestle","year":"2020","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.cpet.2025.01.003_bib18","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ijrobp.2009.04.075","article-title":"Selective nodal irradiation on basis of (18)FDG-PET scans in limited-disease small-cell lung cancer: a prospective study","volume":"77","author":"van Loon","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.cpet.2025.01.003_bib19","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.jtho.2018.09.021","article-title":"Toxicity related to radiotherapy dose and targeting strategy: a pooled analysis of cooperative group trials of combined modality therapy for locally advanced non-small cell lung cancer","volume":"14","author":"Schild","year":"2019","journal-title":"J\u00a0Thorac Oncol"},{"issue":"1","key":"10.1016\/j.cpet.2025.01.003_bib20","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ijrobp.2009.04.045","article-title":"(18)F-FDG PET-CT simulation for non-small-cell lung cancer: effect in patients already staged by PET-CT","volume":"77","author":"Hanna","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1016\/j.cpet.2025.01.003_bib21","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.radonc.2013.02.010","article-title":"The impact of time between staging PET\/CT and definitive chemo-radiation on target volumes and survival in patients with non-small cell lung cancer","volume":"106","author":"Everitt","year":"2013","journal-title":"Radiother Oncol"},{"issue":"12","key":"10.1016\/j.cpet.2025.01.003_bib22","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.21.01308","article-title":"Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"40","author":"Spigel","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.cpet.2025.01.003_bib23","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1097\/JTO.0b013e3182429682","article-title":"Defining local-regional control and its importance in locally advanced non-small cell lung carcinoma","volume":"7","author":"Machtay","year":"2012","journal-title":"J\u00a0Thorac Oncol"},{"issue":"1","key":"10.1016\/j.cpet.2025.01.003_bib24","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1200\/JCO.2016.69.1378","article-title":"Impact of intensity-modulated radiation therapy technique for locally advanced non-small-cell lung cancer: a secondary analysis of the NRG oncology RTOG 0617 randomized clinical trial","volume":"35","author":"Chun","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.cpet.2025.01.003_bib25","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1016\/S1470-2045(24)00320-6","article-title":"Adaptive radiotherapy (up to 74 Gy) or standard radiotherapy (66 Gy) for patients with stage III non-small-cell lung cancer, according to [F]FDG-PET tumour residual uptake at 42 Gy (RTEP7-IFCT-1402): a multicentre, randomised, controlled phase 2 trial","volume":"25","author":"Vera","year":"2024","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.cpet.2025.01.003_bib26","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1007\/s00259-014-2687-9","article-title":"FDG PET during radiochemotherapy is predictive of outcome at 1 year in non-small-cell lung cancer patients: a prospective multicentre study (RTEP2)","volume":"41","author":"Vera","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"10.1016\/j.cpet.2025.01.003_bib27","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.ijrobp.2017.07.036","article-title":"Update of a prospective study of stereotactic body radiation therapy for post-chemoradiation residual disease in stage II\/III non-small cell lung cancer","volume":"99","author":"Kumar","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"10.1016\/j.cpet.2025.01.003_bib28","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.ijrobp.2024.01.217","article-title":"Pneumonitis risk after chemoradiotherapy with and without immunotherapy in patients with locally advanced non-small cell lung cancer: a systematic review and meta-analysis","volume":"119","author":"Han","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"33","key":"10.1016\/j.cpet.2025.01.003_bib29","doi-asserted-by":"crossref","first-page":"3935","DOI":"10.1200\/JCO.24.00022","article-title":"Primary results of NRG-RTOG1106\/ECOG-ACRIN 6697: a randomized phase II trial of individualized adaptive (chemo)Radiotherapy using midtreatment F-fluorodeoxyglucose position emission tomography\/computed tomography in stage III non-small cell lung cancer","volume":"42","author":"Kong","year":"2024","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.cpet.2025.01.003_bib30","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1007\/s00259-005-1878-9","article-title":"Correlation of FDG-PET findings with histopathology in the assessment of response to induction chemoradiotherapy in non-small cell lung cancer","volume":"33","author":"Yamamoto","year":"2006","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"10.1016\/j.cpet.2025.01.003_bib31","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.lungcan.2006.09.028","article-title":"Repeat 18F-FDG PET for monitoring neoadjuvant chemotherapy in patients with stage III non-small cell lung cancer","volume":"55","author":"Eschmann","year":"2007","journal-title":"Lung Cancer"},{"issue":"3","key":"10.1016\/j.cpet.2025.01.003_bib32","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.ijrobp.2020.07.2070","article-title":"RTOG0617 to externally validate blood cell ERCC1\/2 genotypic signature as a radiosensitivity biomarker for both tumor and normal tissue for individualized dose prescription","volume":"108","author":"Kong","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"10","key":"10.1016\/j.cpet.2025.01.003_bib33","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1016\/j.jtho.2020.06.008","article-title":"Radiotherapy-related lymphopenia affects overall survival in patients with lung cancer","volume":"15","author":"Abravan","year":"2020","journal-title":"J\u00a0Thorac Oncol"},{"issue":"8","key":"10.1016\/j.cpet.2025.01.003_bib34","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/S1470-2045(17)30318-2","article-title":"Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial","volume":"18","author":"Faivre-Finn","year":"2017","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.cpet.2025.01.003_bib35","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/S2213-2600(24)00189-9","article-title":"High-dose hyperfractionated simultaneous integrated boost radiotherapy versus standard-dose radiotherapy for limited-stage small-cell lung cancer in China: a multicentre, open-label, randomised, phase 3 trial","volume":"12","author":"Yu","year":"2024","journal-title":"Lancet Respir Med"},{"issue":"2","key":"10.1016\/j.cpet.2025.01.003_bib36","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1053\/j.semnuclmed.2021.12.008","article-title":"The impact of PSMA PET\/CT imaging in prostate cancer radiation treatment","volume":"52","author":"Mena","year":"2022","journal-title":"Semin Nucl Med"},{"issue":"10231","key":"10.1016\/j.cpet.2025.01.003_bib37","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study","volume":"395","author":"Hofman","year":"2020","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.cpet.2025.01.003_bib38","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.2967\/jnumed.118.209387","article-title":"Potential impact of Ga-PSMA-11 PET\/CT on the planning of definitive radiation therapy for prostate cancer","volume":"59","author":"Calais","year":"2018","journal-title":"J\u00a0Nucl Med"},{"issue":"3","key":"10.1016\/j.cpet.2025.01.003_bib39","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/bju.14828","article-title":"Risk of metastatic disease on gallium-prostate-specific membrane antigen positron emission tomography\/computed tomography scan for primary staging of 1253 men at the diagnosis of prostate cancer","volume":"124","author":"Yaxley","year":"2019","journal-title":"BJU Int"},{"issue":"15","key":"10.1016\/j.cpet.2025.01.003_bib40","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1200\/JCO.2006.08.9607","article-title":"Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy","volume":"25","author":"Stephenson","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.cpet.2025.01.003_bib41","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1007\/s00259-021-05222-5","article-title":"Management impact of 18F-DCFPyL PET\/CT in hormone-sensitive prostate cancer patients with biochemical recurrence after definitive treatment: a multicenter retrospective study","volume":"48","author":"Meijer","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"10.1016\/j.cpet.2025.01.003_bib42","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1148\/radiol.211824","article-title":"Effect of 18F-DCFPyL PET\/CT on the management of patients with Recurrent Prostate Cancer: results of a prospective multicenter registry trial","volume":"303","author":"Metser","year":"2022","journal-title":"Radiology"},{"issue":"9","key":"10.1016\/j.cpet.2025.01.003_bib43","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/S1470-2045(19)30415-2","article-title":"F-fluciclovine PET-CT and Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial","volume":"20","author":"Calais","year":"2019","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.cpet.2025.01.003_bib44","doi-asserted-by":"crossref","first-page":"e566","DOI":"10.1097\/RLU.0000000000002703","article-title":"A\u00a0prospective head-to-head comparison of 18F-fluciclovine with 68Ga-PSMA-11 in biochemical recurrence of prostate cancer in PET\/CT","volume":"44","author":"Pernthaler","year":"2019","journal-title":"Clin Nucl Med"},{"issue":"supplement 2","key":"10.1016\/j.cpet.2025.01.003_bib45","article-title":"Role of 18F-Fluciclovine PET\/CT in patients with biochemical recurrence of prostate cancer and a negative PSMA PET\/CT: interim results from a prospective trial","volume":"65","author":"Obala","year":"2024","journal-title":"J\u00a0Nucl Med"},{"issue":"5","key":"10.1016\/j.cpet.2025.01.003_bib46","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","article-title":"Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial","volume":"6","author":"Phillips","year":"2020","journal-title":"JAMA Oncol"},{"issue":"12","key":"10.1016\/j.cpet.2025.01.003_bib47","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.cpet.2025.01.003_bib48","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S1470-2045(24)00135-9","article-title":"[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial","volume":"25","author":"Emmett","year":"2024","journal-title":"Lancet Oncol"},{"issue":"16","key":"10.1016\/j.cpet.2025.01.003_bib49","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13164134","article-title":"Value of combined PET imaging with [F]FDG and [Ga]Ga-PSMA-11 in mCRPC patients with worsening disease during [Lu]Lu-PSMA-617 RLT","volume":"13","author":"Khreish","year":"2021","journal-title":"Cancers"},{"issue":"11","key":"10.1016\/j.cpet.2025.01.003_bib50","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S1470-2045(22)00605-2","article-title":"PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial","volume":"23","author":"Buteau","year":"2022","journal-title":"Lancet Oncol"},{"issue":"2S","key":"10.1016\/j.cpet.2025.01.003_bib51","doi-asserted-by":"crossref","first-page":"e112","DOI":"10.1016\/j.ijrobp.2023.06.891","article-title":"A\u00a0pilot study of stereotactic body radiotherapy and 177Lu-PSMA-617 for oligometastatic hormone sensitive prostate cancer","volume":"117","author":"Imber","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"7","key":"10.1016\/j.cpet.2025.01.003_bib52","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1200\/JCO.2009.24.6298","article-title":"Positron emission tomography with [18F]fluorodeoxyglucose improves staging and patient management in patients with head and neck squamous cell carcinoma: a multicenter prospective study","volume":"28","author":"Lonneux","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.cpet.2025.01.003_bib53","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.ijrobp.2004.08.037","article-title":"Comparison of CT- and FDG-PET-defined gross tumor volume in intensity-modulated radiotherapy for head-and-neck cancer","volume":"61","author":"Paulino","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.cpet.2025.01.003_bib54","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s41824-024-00197-6","article-title":"Efficacy and safety of FDG-PET for determining target volume during intensity-modulated radiotherapy for head and neck cancer involving the oral level","volume":"8","author":"Kosugi","year":"2024","journal-title":"EJNMMI Rep"},{"issue":"1","key":"10.1016\/j.cpet.2025.01.003_bib55","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1148\/radiol.2331030660","article-title":"Tumor volume in pharyngolaryngeal squamous cell carcinoma: comparison at CT, MR imaging, and FDG PET and validation with surgical specimen","volume":"233","author":"Daisne","year":"2004","journal-title":"Radiology"},{"issue":"11","key":"10.1016\/j.cpet.2025.01.003_bib56","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1002\/cncr.20687","article-title":"The role of fluorodeoxyglucose positron emission tomography in cervical lymph node metastases from an unknown primary tumor","volume":"101","author":"Rusthoven","year":"2004","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.cpet.2025.01.003_bib57","first-page":"816","article-title":"FDG PET detection of unknown primary tumors","volume":"41","author":"Bohuslavizki","year":"2000","journal-title":"J\u00a0Nucl Med"},{"issue":"3","key":"10.1016\/j.cpet.2025.01.003_bib58","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1067\/mhn.2000.104807","article-title":"2[F]-fluoro-2-deoxy-D-glucose positron emission tomography is a sensitive tool for the detection of occult primary cancer (carcinoma of unknown primary syndrome) with head and neck lymph node manifestation","volume":"123","author":"Jungeh\u00fclsing","year":"2000","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"3","key":"10.1016\/j.cpet.2025.01.003_bib59","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.radonc.2011.05.028","article-title":"Comparison of intensity-modulated radiotherapy, adaptive radiotherapy, proton radiotherapy, and adaptive proton radiotherapy for treatment of locally advanced head and neck cancer","volume":"101","author":"Simone","year":"2011","journal-title":"Radiother Oncol"},{"issue":"12","key":"10.1016\/j.cpet.2025.01.003_bib60","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.2967\/jnumed.119.227744","article-title":"Prospective evaluation of a tumor control probability model based on dynamic F-FMISO PET for head and neck cancer radiotherapy","volume":"60","author":"Thorwarth","year":"2019","journal-title":"J\u00a0Nucl Med"},{"issue":"23","key":"10.1016\/j.cpet.2025.01.003_bib61","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13235959","article-title":"Hypoxia and its influence on radiotherapy response of HPV-positive and HPV-negative head and neck cancer","volume":"13","author":"Wegge","year":"2021","journal-title":"Cancers"},{"issue":"9","key":"10.1016\/j.cpet.2025.01.003_bib62","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.36407","article-title":"Tumor hypoxia on 18F-fluoromisonidazole positron emission tomography and distant metastasis from head and neck squamous cell carcinoma","volume":"7","author":"Gui","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"18","key":"10.1016\/j.cpet.2025.01.003_bib63","doi-asserted-by":"crossref","first-page":"5435","DOI":"10.1158\/1078-0432.CCR-05-1773","article-title":"Tumor hypoxia imaging with [F-18] fluoromisonidazole positron emission tomography in head and neck cancer","volume":"12","author":"Rajendran","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.cpet.2025.01.003_bib64","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/1754-9485.12155","article-title":"Correlation of p16 status, hypoxic imaging using [18F]-misonidazole positron emission tomography and outcome in patients\u00a0with loco-regionally advanced head and neck\u00a0cancer","volume":"58","author":"Trinkaus","year":"2014","journal-title":"J\u00a0Med Imaging Radiat Oncol"},{"issue":"2","key":"10.1016\/j.cpet.2025.01.003_bib65","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.ijrobp.2024.08.014","article-title":"Interim futility results of NRG-HN005, A randomized, phase II\/III non-inferiority trial for non-smoking p16+ oropharyngeal cancer patients","volume":"120","author":"Yom","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"8","key":"10.1016\/j.cpet.2025.01.003_bib66","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1200\/JCO.23.01308","article-title":"Hypoxia-directed treatment of human papillomavirus-related oropharyngeal carcinoma","volume":"42","author":"Lee","year":"2024","journal-title":"J\u00a0Clin Oncol"},{"issue":"16_suppl","key":"10.1016\/j.cpet.2025.01.003_bib67","doi-asserted-by":"crossref","first-page":"6007","DOI":"10.1200\/JCO.2024.42.16_suppl.6007","article-title":"Intra-treatment hypoxia directed major radiation de-escalation as definitive treatment for human papillomavirus-related oropharyngeal cancer","volume":"42","author":"Lee","year":"2024","journal-title":"J\u00a0Clin Oncol"}],"container-title":["PET Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556859825000033?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556859825000033?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T17:04:17Z","timestamp":1750179857000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556859825000033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":67,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S1556859825000033"],"URL":"https:\/\/doi.org\/10.1016\/j.cpet.2025.01.003","relation":{},"ISSN":["1556-8598"],"issn-type":[{"type":"print","value":"1556-8598"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current Approaches to Radiation Oncology Target Volume Delineation Using PET\/Computed Tomography","name":"articletitle","label":"Article Title"},{"value":"PET Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpet.2025.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}